04/01
Headlines

PFE

Biotech Pre-Market Movers: Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA), Synergy Pharmaceuticals Inc(NASDAQ:SGYP), Pfizer Inc.(NYSE:PFE), AstraZeneca plc (ADR)(NYSE:AZN)

Ryan Holtz03 mins

The American Despositary Receipts of Teva Pharmaceutical Industries Ltd (ADR)(NYSE:TEVA) edged up in recent pre-market trading on Monday after announcing over the weekend an agreement it has signed with Takeda Pharmaceutical for the marketing and sale of Rasagiline in Japan. Rasagiline is a treatment for Parkinson’s Disease developed by TEVA and has been approved in…

Read More

AstraZeneca plc (ADR)(NYSE:AZN) Shares Soar Pre-Market

Chris Lewis01 mins

Shares of AstraZeneca plc (ADR)(NYSE:AZN) reached a new high in pre-market trading as Pfizer Inc.(NYSE:PFE) confirmed it has attempted to renew negotiations on a possible merger. Pfizer submitted a preliminary indication of interest to the board of directors of AstraZeneca in January 2014 regarding the possible merger. AstraZeneca declined to pursue negotiations at that time, but…

Read More
FB Nasdaq FB Facebook

Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Ariad Pharmaceuticals (NASDAQ:ARIA), Johnson & Johnson (NYSE:JNJ)

Kristen Barton03 mins

A proxy advisory firm has asked shareholders of the Indian unit of Wyeth to oppose its merger deal with Pfizer Inc. (NYSE:PFE) as the share swap ratio is skewed in favour of Pfizer Inc. (NYSE:PFE). Shareholder Empowerment Services (SES) has made this suggestion ahead of the shareholder meeting this week. Pfizer Inc. (NYSE:PFE) stock performance…

Read More

Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis12 mins

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session…

Read More

Healthcare Most Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Teva Pharmaceutical Industries (NYSE:TEVA), Bristol-Myers Squibb (NYSE:BMY)

Jayne Crisman02 mins

During the trial, palbociclib — a pill — was combined with the standard anti-estrogen treatment Letrozole. The combined treatment resulted in a 26.1 month progression-free survival rate compared with only 7.5 months for Letrozole alone. Under development by Pfizer Inc. (NYSE:PFE), the medication used in the study is a selective inhibitor of cyclin-dependent kinases (CDK)…

Read More

Healthcare active runners: Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD)

Jason Knox02 mins

On Monday, Johnson & Johnson (NYSE:JNJ) announced that it accepted the binding offer from The Carlyle Group (NASDAQ:CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. Johnson & Johnson (NYSE:JNJ) stock performance was 0.16% in last session and finished the…

Read More